Bibliography
- Influenza (seasonal). World health Organization. Fact sheet No 211. Geneva, Switzerland: WHO, 2009. Available from: www.who.int/mediacentre/factsheets/fs211/en/index.html [Last accessed 11 November 2010]
- Belshe RB, Ambrose CS, Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 2008;26(Suppl 4):D10-16
- Palache AM, Scheepers HSJ, de Regt V, Safety, reactogenicity and immunogenicity of Madin Darbin Canine Kidney cell-derived inactivated influenza subunit vaccine: a meta-analysis of clinical studies. Dev Biol Stand 1999;98:115-25
- Halperin SA, Smith B, Mabrouk T, Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 2002;20:1240-7
- Ghendon YZ, Markushin SG, Akopova II, Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine. Vaccine 2005;23:4678-84
- Bruhl P, Kerschbaum A, Kistner O, Humoral and cell-mediated immunity to vero cell-derived influenza vaccine. Vaccine 2000;19:1149-58
- Influenza – Seasonal influenza Vaccine. Leiden, The Netherlands: Crucell, 2009. Available from: http://www.crucell.com/R_and_D-Clinical_Development-Epidemic_Influenza_Vaccine [Last accessed 11 November 2010]
- Hoelscher MA, Jayashankar L, Garg S, New pre-pandemic influenza vaccine: an egg- and adjuvant-independent human adenoviral vector strategy inducing long lasting protective immune responses in mice. Clin Pharmacol Ther 2007;82:665-71
- Van Kampen KR, Shi Z, Gao P, Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 2005;23:1029-36
- Richardson T. Novavax Announces Favourable Interim Results from Human Clinical Trial for its Pandemic Influenza Vaccine Program. Rockville, MD: Novavax, December 2007. Available from: http://www.novavax.com/download/releases/pandemicinterimresultsPR%20FO.pdf [Last accessed 11 November 2010]
- Smith LR, Wloch MK, Ye M, Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 haemoaggluitinin. Vaccine 2010;16:2565-72
- Price GE, Soboleski MR, Lo CY, Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H1N5 influenza A viruses. Vaccine 2009;27:6512-21
- Huang J, Garmise RJ, Crowdre TM, A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine 2004;23:794-801
- Amorij JP, Saluja V, Petersen AH, Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine 2007;25:8707-17
- Chen D, Burger M, Chu Q, Epidermal powder immunization: cellular and molecular mechanisms for enhancing vaccine immunogenicity. Virus Res 2004;103:147-53
- Kim YC, Quan FS, Yoo DG, Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine 2009;27:6932-8
- Pearton M, Kang SM, Song JM, Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin. Vaccine 2010;28:6104-13
- Raphael AP, Prow TW, Crichton ML, Targeted, needle-free vaccinations in skin using multilayered, densely-packed dissolving microprojection arrays. Small 2010;6:1785-93
- Tumpey TM, Renshaw M, Clements JD, Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 2001;75:5141-50
- Seo KY, Han SJ, Cha HR, Eye mucosa: an efficient vaccine delivery route for inducing protective immunity. J Immunol 2010;185:3610-19